The National Comprehensive Cancer Network® (NCCN®) has released a new resource aimed at helping individuals understand ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic ...

Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

A systematic review found that while genomic classifier (GC) tests may influence risk classifications or treatment decisions for patients with localized prostate cancer (PCa), there is a need for ...

Incorporating biomarkers into standard practice enhances diagnostic accuracy, supporting confident treatment decisions and optimizing care.

Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.

Panel participants share an optimistic outlook for integrating new innovations, tacking community-level challenges, and more.

Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

导 ...